Macleods Pharmaceuticals IPO
Macleods Pharmaceuticals, Mumbai-based drug is set to raise funds worth Rs. 5000 crores and has filed preliminary papers...
- Status: Upcoming
-
-
/
-
shares
Minimum Investment
IPO Details
-
Open Date
TBA
-
Close Date
TBA
-
Listing Date
TBA
- IPO Price Range
TBA
- IPO Size
TBA
- Listing Exchange
TBA
IPO Timeline
Last Updated: 18 July 2023 4:52 PM by 5Paisa
Mumbai-based, Macleods Pharmaceuticals was established in 1989, and is the 7th largest drug firm in Indian Pharmaceutical Market based on domestic sales. The company earns 80% of the domestic sales from non-metros(higher than 70.0% as recorded for the IPM) and 20% from the metros.
The company is engaged in developing, manufacturing, and marketing a wide range of formulations and known for its anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment brand and has a significant presence in North and East India.
Sales from anti-diabetics, cardiovascular, derma, respiratory and hormones therapies grew at a CAGR of 28.5%, 13.4%, 11.7%, 11.0%, and 10.4%, respectively, higher than the IPM growth of 12.3%, 11.1%, 10.8%, 6.2% and 6.9%, for the same therapies in the same periods
The drug firm launched new brands in the last three Fiscals, such as Vildamac and Vildamac M, in the anti-diabetic market, has gained market share among non-innovator brands in the IPM (Vildamac comprised 7.3% of the Vildagliptin market, and Vildamac M comprised a market share of 8.6% of the Vildagliptin+Metformin market) by domestic sales
The company has presence in more than 170 countries across developed and emerging markets in North America, Europe, Africa, Asia, South America etc
Macleods also has an extensive portfolio of anti-TB products, and has the highest number of WHO prequalified anti-TB products globally with 32 registrations.
| Particulars (in Rs. Crores) | FY21 | FY20 | FY19 |
|---|---|---|---|
| Revenue | 7199.4 | 6902.8 | 5870.4 |
| EBITDA | 2096.7 | 1724.3 | 1340.9 |
| PAT | 1630.7 | 1461.2 | 1192.1 |
| Particulars (in Rs. Crores) | FY21 | FY20 | FY19 |
|---|---|---|---|
| Total Assets | 5734.7 | 9573.4 | 7568.9 |
| Share Capital | 20.0 | 20.0 | 20.0 |
| Total Borrowings | 79.7 | 36.1 | 131.9 |
| Particulars (in Rs. Crores) | FY21 | FY20 | FY19 |
|---|---|---|---|
| Net cash generated from / (used in) operating activities | 1268.46 | 1373.42 | 694.21 |
| Net cash from / (used in) investing activities | -1337.59 | -1164.58 | -785.53 |
| Net cash flow from / (used in) financing activities | 29.50 | -108.58 | 63.14 |
| Net increase (decrease) in cash and cash equivalents | -39.64 | 100.27 | -28.18 |
Peer Comparison
| Name of the Company | Total Revenue | Basic EPS | Nav Rs. per share | PE | RoNW% |
|---|---|---|---|---|---|
|
Macleods Pharmaceuticals Limited |
7,199.4 | 33.74 | 63.37 | NA | 53.3% |
| Torrent Pharmaceuticals Limited | 8004.8 | 73.98 | 344.94 | 35.11 | 21.5% |
| Alkem Laboratories Limited | 8865.0 | 132.57 | 632.13 | 26.41 | 21.4% |
|
Sun Pharmaceutical Industries Limited |
33498.1 | 12.1 | 206.22 | 73.91 | 4.6% |
| Dr. Reddy's Laboratories Limited | 19047.5 | 117.67 | 1,064.51 | 37.25 | 11.1% |
| Lupin Limited | 15163.0 | 26.84 | 305.46 | 30.18 | 8.9% |
| Cadila Healthcare Limited | 15102.2 | 20.84 | 145.83 | 19.26 | 14.64% |
| Eris Lifesciences Limited | 1211.9 | 26.16 | 116.1 | 26.76 | 22.53% |
| Ipca Laboratories Limited | 5420.0 | 90.11 | 371.79 | 11.14 | 24.20% |
Strengths
1. One of the Leading and Fast-Growing Companies with Significant Presence in the IPM
2. Proven Track Record of Building Brands
3. Diversified Presence across Global Markets with Calibrated Business Model
4. R&D-Led Differentiated Portfolio of Products
5. Diversified and quality-compliant manufacturing capabilities
Risks
1. It may experience a shortfall in the supply of the raw materials or an increase in their prices, or of other input costs.
2. It could experience a material slowdown or shutdown in the manufacturing or R&D operations
3. Failure to meet various quality standards and good manufacturing practices may result in increased product liabilities
4. It derives a significant portion of its revenue from operations from a limited number of markets
in 3
easy steps
Using 5paisa App or
Website
to block Payment
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Macleods Pharmaceuticals IPO details are yet to be announced.
Macleods Pharmaceuticals IPO details are yet to be announced.
Macleods Pharmaceuticals IPO details are yet to be announced.
The IPO comprises entirely of an offer for sale comprising 60.5 million equity shares by promoters.
Macleods Pharmaceuticals is promoted by Girdharilal Bawri, Banwarilal Bawri and Dr. Rajendra Agarwal
Macleods Pharmaceuticals IPO details are yet to be announced.
Macleods Pharmaceuticals IPO details are yet to be announced.
Kotak Mahindra Capital Company, Citigroup Global Markets India, Edelweiss Financial Services, ICICI Securities and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers to the issue.
The proceeds from the issue will be used for:
1. carry out the Offer for Sale of up to 60,482,040 Equity Shares by the selling shareholders
2. enhance the visibility and brand image as well as provide a public market for the equity shares in India.
To apply for the IPO, follow the steps given below
1. Login to your 5paisa account and select the issue in the current IPO section
2. Enter the number of lots and price at which you wish to apply for
3. Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange
4. You will receive a mandate notification to block funds in your UPI app